The latest biotech news

News and Trends 1 Jul 2016

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

The GMO debate is back into mainstream news, as 110 Nobel laureates (out of the 297 living) signed a ‘cease and desist’ open letter to Greenpeace. The target is its anti-GMO campaign, which they deem anti-scientific. And Golden Rice is the spearhead of the accusations… How many poor people in the world must die before […]

July 1, 2016 - 5 minutesmins - By Denise Neves Gameiro

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

biotech discuva cambridge drug discovery brexit header

News and Trends 1 Jul 2016

Drug-resistant Bacteria should fear Discuva’s antimicrobials

Duty calls on the Island of Queen Elizabeth II…. What will be the future of Biotech in the United Kingdom and in Europe? Last week we did a review to catch up with all the details of #Brexit and this is why we decided to head up to Cambridge, one of the major biotech and research centers in the […]

July 1, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2016

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma. Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO […]

June 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

nash evotec biotech accellerate ellersbrook pharma liver steatohepatitis

News and Trends 30 Jun 2016

Germany joins the Biotech Front against a ‘Silent Epidemic’ of the Liver

The German life sciences investor, Ellersbrook, is putting millions into Evotec‘s drug discovery program. Together the two join a biotech industry hunt for a therapy against a metabolic liver disease (NASH) that affects 30% of adults worldwide. Ellersbrook is a life science focused investment firm owned by Herbert Stadler, a renowned biotech entrepreneur. It is now looking to accelerate […]

June 30, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Jun 2016

11 Hot Companies to Meet this Year at BioSpain

Spain has a lot of great stuff – paella, tapas, siesta! But how is Spanish biotech doing? With BioSpain 2016 approaching, we took a look at some of the most important biotechs operating in Spain and attending the event. Bonus: here is a promotional code to have a discount of 10% on your ticket BIO2016 As one […]

June 30, 2016 - 5 minutesmins - By Denise Neves Gameiro

affiris peptide vaccine affitope cholesterol

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

celyad c cure chart1 ischemic heart failure

News and Trends 29 Jun 2016

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have a positive effect in a part of the patients. True potential or public relations patch? Cardiovascular diseases are the leading cause of death worldwide. Biotech solutions in the field range from gene therapy (with uniQure and […]

June 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jun 2016

How to Survive the Valley of Death as a Biotech Startup?

Over the past decade there has been an unprecedented restructuring of R&D in pharma whereas building a successful biotech company is still as challenging. How can these two elements help each other? This is a contributing post from Peter Machin, former SVP Drug Discovery at GSK. Big Pharma has significantly contracted its in-house […]

June 29, 2016 - 5 minutesmins - By External Contributor

News and Trends 28 Jun 2016

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

MSD has received EMA pre-approval for its famous anti-PD-1 therapy, Keytruda. It could soon be used to treat non-small cell lung cancer (NSCLC), the deadliest type of cancer. Checkpoint inhibitors are a key strategy in the hype field of immuno-oncology. This kind of cancer therapy blocks the natural ‘safety checks’ of the immune system – […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 28 Jun 2016

What’s the Truth about Gender Diversity in Biotech?

The diversity debate in biotech has always been there. In the month of Pride and after LifeSci’s party scandal at JPMorgan 2016, I was wondering what’s the real situation about diversity in biotech? And what could be the solutions? Haven’t you heard about the LifeSci’s party scandal? In short: the editor of BioCentury Karen Bernstein […]

June 28, 2016 - 5 minutesmins - By Philip Hemme

molmed graft host disease zalmoxis leukemia

News and Trends 28 Jun 2016

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem cells. This is a big step forward in a key treatment for blood cancers. A transplant of hematopoietic stem cells (cells that give origin to blood cells) is often used as part of treatments for […]

June 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Drug-resistant Bacteria should fear Discuva’s antimicrobials

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Germany joins the Biotech Front against a ‘Silent Epidemic’ of the Liver

11 Hot Companies to Meet this Year at BioSpain

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

How to Survive the Valley of Death as a Biotech Startup?

And now, Immuno-oncology gets EMA’s pre-approval for Lung Cancer

What’s the Truth about Gender Diversity in Biotech?

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!